Biocryst Pharmaceuticals Inc   (BCRX)
Other Ticker:  
Price: $6.1300 $-0.20 -3.160%
Day's High: $6.445 Week Perf: 0.00
Day's Low: $ 6.11 30 Day Perf: 47.36 %
Volume (M): 2,148 52 Wk High: $ 8.96
Volume (M$): $ 13,165 52 Wk Avg: $6.18
Open: $6.38 52 Wk Low: $4.03

 Market Capitalization (Millions $) 1,263
 Shares Outstanding (Millions) 206
 Employees 192
 Revenues (TTM) (Millions $) 355
 Net Income (TTM) (Millions $) -209
 Cash Flow (TTM) (Millions $) -70
 Capital Exp. (TTM) (Millions $) 2

Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc.
is a biotechnology company based in Durham, North Carolina that focuses on developing innovative drugs for the treatment of rare diseases.
The company primarily focuses on developing small-molecule drugs designed to target specific enzymes or proteins in the body that are involved in the disease process.
Biocryst's current pipeline includes a diverse range of drug candidates, including orally-administered treatments for hereditary angioedema (HAE), a rare genetic disorder that causes sudden and severe swelling attacks; Alport syndrome, a rare genetic disorder that affects the kidneys and can lead to kidney failure; and non-alcoholic steatohepatitis (NASH), a type of liver disease that is associated with obesity and diabetes.
Their lead candidate is Orladeyo, an oral medication approved by the FDA for the prevention of HAE attacks in adults and adolescents over the age of 12.
Biocryst is also continuing to work on new indications for Orladeyo and is exploring the potential for it to be used in combination with other medications or as a monotherapy.
Another key focus area for Biocryst is developing antiviral drugs.
They have several candidates in their program, including Galidesivir, which has shown promise in treating a number of viral diseases, including influenza, Ebola, and most recently, COVID-19.
Overall, Biocryst Pharmaceuticals Inc.
has a strong track record of developing innovative drugs to treat rare diseases, and their ongoing research and development efforts position them as a leader in the biotechnology industry.

   Company Address: 4505 Emperor Blvd., Suite 200 Durham 27703 NC
   Company Phone Number: 859-1302   Stock Exchange / Ticker: NASDAQ BCRX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

ORLADEYO Receives Regulatory Green Light in Mexico: Revamping the Treatment of Hereditary Angioedema

Published Mon, May 13 2024 11:00 AM UTC

In a groundbreaking development, BioCryst Pharmaceuticals, Inc. has recently announced the approval of its oral, once-daily medication ORLADEYO (berotralstat) by the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico. This approval marks a significant milestone in the management and prevention of hereditary angioedema (HAE) attacks in both adult and ...

Clinical Study

ORLADEYO: Evolving HAE Treatment and Reducing Healthcare Burden with Significant HRU Reductions

Published Thu, May 9 2024 11:00 AM UTC

BioCryst's ORLADEYO Shows Promising Reductions in Healthcare Resource Utilization for Patients with HAE: A Breakthrough in HAE Treatment Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of swelling in various body parts, including the face, limbs, genitals, and gastrointestinal tract. These episodes can be painful, disfiguring, and p...

Biocryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc Achieves Remarkable Financial Results in Q1 2024

BioCryst Pharmaceuticals Inc Reports Improved Financial Performance in Q1 2024
May 07, 2024 - BioCryst Pharmaceuticals Inc (Nasdaq:BCRX) has released its financial results for the first quarter of 2024, showcasing positive developments compared to the previous year. The biotechnology and pharmaceutical company reported a decrease in its loss per share, improved earnings per share, and a significant jump in revenue.
During the financial first quarter of 2024, BioCryst Pharmaceuticals Inc decreased its loss per share to $-0.17 from $-0.28 in the same period the previous year. Additionally, the company's earnings per share improved from $-0.30 in the previous financial reporting period. This indicates that BioCryst Pharmaceuticals Inc is making progress towards profitability.

Financing Agreement

BioCryst Pharmaceuticals Faces Financial Challenges Amidst Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published Fri, May 3 2024 11:00 AM UTC

BioCryst Pharmaceuticals Grants Stock Options and RSUs as Inducements to New Employees, Faces Challenges Amidst Cumulative Net Loss
In a recent announcement, BioCryst Pharmaceuticals, Inc. revealed that the compensation committee of its board of directors granted 10 newly-hired employees stock options and restricted stock units (RSUs) as inducements to join the company....

Product Service News

Brazilian Health Regulatory Agency Approves BioCryst's ORLADEYO for the Treatment of Hereditary Angioedema (HAE)

Published Wed, Apr 17 2024 8:31 AM UTC

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) has recently announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for ORLADEYO (berotralstat) to be used as a once-daily oral prophylaxis treatment for hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older. This breakthrough approval brings new hope for HAE pati...


Biocryst Pharmaceuticals Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Biocryst Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Biocryst Pharmaceuticals Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com